title: [Contraception and adolescence].
abstract: The mean age of first sexual intercourse is still around 17 in France, but a lot of teenagers are concerned by contraception before, with approximately 25% of sexually active 15-year-old girls. The contraceptive method must take into consideration some typical features of this population, as sporadic and non-planned sexual activity, with several sexual partners in a short period of time. In 2004, the "Haute Autorité de santé" has recommended, as first-line method, combined oral contraceptive (COC) pills, in association with male condoms. Copper-containing intrauterine contraceptive devices (IUCD) and etonogestrel-containing subcutaneous implant have been suggested but not recommended. However, oral contraceptive pill, as a user-based method, carries an important typical-use failure rate, because remembering taking a daily pill, and dealing with stop periods, may be challenging. Some easier-to-use method should be kept in mind, as 28-day COC packs, transdermal contraceptive patches, and vaginal contraceptive rings. Moreover, American studies have shown that long-acting reversible contraceptives (LARC), i.e. IUCD and implant, have many advantages for teenagers: very effective, safe, invisible. They seem well-fitted for this population, with high satisfaction and continuation rates, as long as side effects are well explained. Thus, LARC methods should be proposed more widely to teenagers. Anyway, before prescribing a contraceptive method, it is important to determine the specific situation of every teenager, to let them choose the method that they consider as appropriate in their own case, and to think about the availability of the chosen method. It is necessary to explain how to handle mistakes or misses with user-based contraceptive methods, and emergency contraception can be anticipated and prescribed in advanced provision. The use of male condoms should be encouraged for adolescents, with another effective contraceptive method, in order to reduce the high risk of sexually transmitted infections (STI) in this population.
authors.affiliation: Service de gynécologie-obstétrique, hôpital Beaujon, Assistance publique des Hôpitaux de Paris, université Paris VII, 100, boulevard du Général-Leclerc, 92118 Clichy cedex, France. pascale.amate@bjn.aphp.fr
authors.forename: P
authors.initials: P
authors.lastname: Amate
authors.forename: D
authors.initials: D
authors.lastname: Luton
authors.forename: C
authors.initials: C
authors.lastname: Davitian
mesh_terms: D000028:Abortion, Induced / Q000706:statistics & numerical data; D000279:Administration, Cutaneous; D000293:Adolescent; D000294:Adolescent Behavior; D002755:Choice Behavior; D003075:Coitus; D017280:Condoms; D003267:Contraception / Q000379:methods*; D044363:Contraception, Postcoital; D003270:Contraceptive Agents / Q000008:administration & dosage; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D003273:Contraceptive Devices; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004343:Drug Implants; D005260:Female; D005602:France; D006297:Health Services Accessibility; D006801:Humans; D007434:Intrauterine Devices; D008297:Male; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D010817:Physician-Patient Relations; D011247:Pregnancy; D012747:Sexual Partners; D012749:Sexually Transmitted Diseases / Q000517:prevention & control
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D004343:Drug Implants